Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital upgrades Dunelm, says valuation is undemanding

(Sharecast News) - RBC Capital Markets upgraded Dunelm on Tuesday to 'outperform' from 'sector perform' as it said the stock's valuation was undemanding. The bank said that looking at the industry data, UK home-related retail had a tough year in 2024, but it's encouraged by Dunelm's ability to grow its sales and take market share despite this.

"Its model remains well run and cash generative, and it has more runway for growth now, given its recent acquisition in Ireland," RBC said. "As such, 12x CY25 estimated price-to-earnings feels undemanding to us, and we upgrade to outperform."

The bank also said Dunelm has a strong track record of additional cash returns, having returned more than £700mn of cash via special dividends since its IPO in 2006.

RBC said it forecasts a 25p per share special dividend to be announced at Dunelm's first-half results later this month.

"Even with this, we expect Dunelm to end FY25 towards the lower end of its 0.2-0.6x target net debt/EBITDA corridor," it said. "As such, it should have ample headroom for additional cash returns to continue."

RBC forecasts total special dividends of around £195mn between FY25-27 but estimates that the homeware retailer has the firepower to return at least another £100mn, without exceeding its leverage targets.

The bank maintained its 1,175p price target on the stock.

At 0950 GMT, the shares were up 2.8% at 988.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.